Foetal safety of old and new antiepileptic drugs

Bibliography

• Reimers A, Brodtkorb E. Second-generation antiepileptic drugs and pregnancy: a guide for clinicians. Expert Rev Neurother 2012;12:707-17
   PubMed Web of Science ®Google Scholar
• Kluger S, Meador K. Teratogenicity of antiepileptic drugs. Semin Neurol 2008;328-35
   PubMed Web of Science ®Google Scholar
• Tomson T, Battino D. Teratogenic effects of antiepileptic medications. Neurol Clin 2009;993-1002
   PubMed Web of Science ®Google Scholar
• Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 2004;6:57-75
   PubMed Web of Science ®Google Scholar
• Campbell E, Devenney E, Morrow J, et al. Recurrence risk of congenital malformations in infance exposed to antiepileptic drugs in utero. Epilepsia 2013;54:165
   PubMed Web of Science ®Google Scholar
• Schachter SC, Yerby MS. Management of epilepsy: pharmacologic therapy and quality-of-life issues. Postgrad Med 1997;101:133-8
   PubMed Web of Science ®Google Scholar
• Tomson T, Battino D, Bonizzoni E, et al. EURAP study group. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011;10:609-17
   PubMed Web of Science ®Google Scholar
• Landmark CJ, Fossmark H, Larsson PG, et al. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. Epilepsy Res 2011;95:51-9
   PubMed Web of Science ®Google Scholar
• Ardinger H, Atkin J, Blackston R, et al. Verification of the fetal valproate syndrome phenotype. Am J Med Genet 1988;29:171-85
   PubMed Web of Science ®Google Scholar
• Chevallier B, Negre V, Bidat E, Lagardere B. Fetal valproate syndrome and somatic and psychomotor development. Arch Franc Pediatr 1989;46:627-30
   PubMedGoogle Scholar
• Clayton-Smith J, Donnai D. Fetal valproate syndrome. J Med Genet 1995;32:724-7
   PubMed Web of Science ®Google Scholar
• Hanson JW, Myrianthopoulos NC, Sedgwick-Harvey MA, Smith DW. Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. J Pediat 1976;89:662-8
   PubMed Web of Science ®Google Scholar
• Winter R, Donnai D, Burn J, Tucker S. Fetal valproate syndrome: Is there a recognisable phenotype? J Med Genet 1987;24:692-5
   PubMed Web of Science ®Google Scholar
• Bromley RL, Mawer G, Love J, et al. Early cognitive development in children born to women with epilepsy: A prospective report. Epilepsia 2010;51:2058-65
   PubMed Web of Science ®Google Scholar
• Cummings C, Stewart M, Stevenson M, et al. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child 2011;96:643-7
   PubMed Web of Science ®Google Scholar
• Meador K, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. New Eng J Med 2009;360:1597-605
   PubMed Web of Science ®Google Scholar
• Nadebaum C, Anderson V, Vajda F, et al. The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. J Int Neuropsychol Soc 2011;17:133-42
   PubMed Web of Science ®Google Scholar
• Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Eng J Med 2001;344:1132-8
   PubMed Web of Science ®Google Scholar
• Jentink J, Dolk H, Loane MA, et al. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ 2010;341:c6581
   PubMed Web of Science ®Google Scholar
• Martin JA, Hamilton BE, Ventura SJ, et al. Births: final data for 2009. Natl Vital Stat Rep 2011;60:1-70
   PubMedGoogle Scholar
• Hernandez-Diaz S, Smith CR, Wyszynski DF, Holmes LB. Major malformations among infants exposed to carbamazepine during pregnancy (Teratology Society Abstracts). Birth Defects Res A Clin Mol 2007;79:357
   Web of Science ®Google Scholar
• Ornoy A. Neuroteratogens in man: an overview with special emphasis on the teratogenicity of antiepileptic drugs in pregnancy. Reprod Toxicol 2006;22:214-26
   PubMed Web of Science ®Google Scholar
• Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006;77:193
   PubMed Web of Science ®Google Scholar
• Holmes LB, Mittendorf R, Shen A, et al. Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Arch Neurol 2011;68:1275-81
   PubMed Web of Science ®Google Scholar
• Meador KJ, Reynolds RW, Crean S, et al. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 2008;81:1-13
   PubMed Web of Science ®Google Scholar
• Matalon S, Schechtman S, Goldzweig G, Ornoy A. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol 2002;16:9-17
   PubMed Web of Science ®Google Scholar
• Wide K, Henning E, Eomson T, Winbladh B. Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatr 2002;91:409-14
   PubMed Web of Science ®Google Scholar
• Baker GA, Bromley RL, Briggs M, et al. IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology 2015;84:382-90
   PubMed Web of Science ®Google Scholar
• Bromley R, Weston J, Adab N, et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev 2014;30:10 CD010236
   Google Scholar
• Hanson JW, Smith DW. The fetal hydantoin syndrome. J Pediatr 1975;87:285-90
   PubMed Web of Science ®Google Scholar
• Singh R, Kumar N, Arora S, et al. Fetal hydantoin syndrome and its anaesthetic implications: A case report. Case Rep Anesthesiol 2012;370412
   Google Scholar
• Jones KI. Smith’S recognizable patterns of human malformation. 5th edition. WB. Saunders; Philadelphia, PA, USA: 1997
   Google Scholar
• Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology 2006;67:407-12
   PubMed Web of Science ®Google Scholar
• Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the quality standards subcommittee and therapeutics and technology assessment subcommittee of the american academy of neurology and american epilepsy society. Neurology 2009;73:126-32
   PubMed Web of Science ®Google Scholar
• Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology 2006;67:407-12
   PubMed Web of Science ®Google Scholar
• Satgé D, Sasco AJ, Little J. Antenatal therapeutic drug exposure and fetal/neonatal tumours: review of 89 cases. Paediatr Perinat Epidemiol 1998;12:84-117
   PubMed Web of Science ®Google Scholar
• Artama M, Auvinen A, Raudaskoski T, et al. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 2005;64:1874-8
   PubMed Web of Science ®Google Scholar
• Veiby G, Daltveit AK, Schjølberg S, et al. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia 2013;54:1462-72
   PubMed Web of Science ®Google Scholar
• Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000;343:1608-14
   PubMed Web of Science ®Google Scholar
• Adab N, Tudur Smith C, Vinten J, et al. Common antiepileptic drugs in pregnancy in women with epilepsy (Review). Cochrane Data Sys Rev 2004(Issue 3):CD004848
   Google Scholar
• Thomas S, Ajaykumar B, Singhu K, et al. Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy Behav 2008;13:229-36
   PubMed Web of Science ®Google Scholar
• Leavitt A, Yerby M, Robinson N, et al. Epilepsy in pregnancy: developmental outcome of offspring at 12 months. Neurology 1992;42:141-3
   PubMed Web of Science ®Google Scholar
• Rovet J, Cole S, Nulman I, et al. Effects of maternal epilepsy on children’s neurodevelopment. Child Neuropsychol 1995;1:150-7
   Web of Science ®Google Scholar
• Holmes LB, Wyszynski DF, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol 2004;61:673-8
   PubMed Web of Science ®Google Scholar
• Hernández-Díaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012;78:1692
   PubMed Web of Science ®Google Scholar
• Tica OS, Tica AA, Brailoiu CG, et al. Sirenomelia after phenobarbital and carbamazepine therapy in pregnancy. Birth Defects Res A Clin Mol Teratol 2013;97:425-8
   PubMed Web of Science ®Google Scholar
• Reinisch JM, Sanders SA, Mortensen EL, Rubin DB. In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA 1995;274:1518-25
   PubMed Web of Science ®Google Scholar
• Thomas S, Sukumaran S, Lukose N, et al. Intellectual and language functions in children of mothers with epilepsy. Epilepsia 2007;48:2234-40
   PubMed Web of Science ®Google Scholar
• Vajda FJ, O’Brien TJ, Lander CM, et al. Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia 2013;54:181-6
   PubMed Web of Science ®Google Scholar
• Lindhout D, Omtzigt JG, Cornel MC. Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs. Neurology 1992;42:111
   PubMed Web of Science ®Google Scholar
• Lindhout D, Schmidt D. In utero exposure to valproate and neural-tube defects. Lancet 1986;2:1932
   Google Scholar
• Kini U, Adab N, Vinten J, et al. Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsant syndromes. Arch Dis Child Fetal Neonatal Ed 2006;91:F90
   PubMed Web of Science ®Google Scholar
• Perucca E, Tomson T. Prenatal exposure to antiepileptic drugs. Lancet 2006;367:1467
   PubMed Web of Science ®Google Scholar
• Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia 2009;50:2130
   PubMed Web of Science ®Google Scholar
• Bromfield EB, Dworetzky BA, Wyszynski DF, et al. Valproate teratogenicity and epilepsy syndrome. Epilepsia 2008;49:2122
   PubMed Web of Science ®Google Scholar
• Wyszynski DF, Nambisan M, Surve T, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005;64:961
   PubMed Web of Science ®Google Scholar
• Jentink J, Loane MA, Dolk H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010;362:2185
   PubMed Web of Science ®Google Scholar
• Vajda FJ. Effect of anti-epileptic drug therapy on the unborn child. J Clin Neurosci 2014;21:716-21
   PubMed Web of Science ®Google Scholar
• Vajda FJ, Eadie MJ. Maternal valproate dosage and foetal malformations. Acta Neurol Scand 2005;112:137
   PubMed Web of Science ®Google Scholar
• Bavoux F, Fournier-Perhilou AI, Wood C, et al. Neonatal fibrinogen depletion caused by sodium valproate. Ann Pharmacother 1994;28:1307
   PubMed Web of Science ®Google Scholar
• Majer RV, Green PJ. Neonatal afibrinogenaemia due to sodium valproate. Lancet 1987;2:740
   PubMed Web of Science ®Google Scholar
• Mole TB, Marson A, Appleton R. Withholding the choice of sodium valproate to young women with generalised epilepsy: are we causing more harm than good? Seizure 2015;24:127-30
   PubMed Web of Science ®Google Scholar
• Dean JCS, Hailey H, Moore SJ, et al. Long term health and neurodevelopment in children with prenatal exposure to antiepileptic drugs before birth. J Med Gen 2002;39:251-9
   PubMed Web of Science ®Google Scholar
• Bromley R. Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology 2008;71:1923-5
   PubMed Web of Science ®Google Scholar
• Hill DS, Wlodarczyk BJ, Palacios AM, Finnell RH. Teratogenic effects of antiepileptic drugs. Expert Rev Neurother 2010;10:943-59
   PubMed Web of Science ®Google Scholar
• Montouris G. Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry. Epilepsy Behav 2003;4:310-17
   PubMed Web of Science ®Google Scholar
• Velez-Ruiz NJ, Meador KJ. Neurodevelopmental effects of fetal antiepileptic drug exposure. Drug Saf 2015;3:271-8
   Web of Science ®Google Scholar
• Holmes LB, Hernandez-Diaz S. Newer anticonvulsants: lamotrigine, topiramate and gabapentin. Birth Defects Res A Clin Mol Teratol 2012;94:599-606
   PubMed Web of Science ®Google Scholar
• Cunnington M, Tennis P. Lamotrigine and the risk of malformations in pregnancy. Neurology 2005;64:955-60
   PubMed Web of Science ®Google Scholar
• Holmes LB, Baldwin EJ, Smith CR, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008;70:2152-8
   PubMed Web of Science ®Google Scholar
• Dolk H, Jentink J, Loane M, et al. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology 2008;71:714-22
   PubMed Web of Science ®Google Scholar
• Sabers A, Dam M, A-Rogvi-Hansen B, et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand 2004;109:9-13
   PubMed Web of Science ®Google Scholar
• Mølgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 2011;305:1996-2002
   PubMed Web of Science ®Google Scholar
• Cunnington M, Ferber S, Quartey G. Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study. Epilepsia 2007;48:1207-10
   PubMed Web of Science ®Google Scholar
• Cunnington MC, Weil JG, Messenheimer JA, et al. Final results from 18 years of the International Lamotrigine Pregnancy Registry. Neurology 2011;76:1817-23
   PubMed Web of Science ®Google Scholar
• Mawhinney E, Craig J, Morrow J, et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology 2013;80:400-5
   PubMed Web of Science ®Google Scholar
• Shallcross R, Bromley R, Irwin B, et al. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology 2011;76:383-9
   PubMed Web of Science ®Google Scholar
• Shallcross R, Bromley RL, Cheyne CP, et al. In utero exposure to levetiracetam vs valproate: Development and language at 3 years of age. Neurology 2014;82:213-21
   PubMed Web of Science ®Google Scholar
• Bülau P1, Paar WD, von Unruh GE. Pharmacokinetics of oxcarbazepine and 10-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother. Eur J Clin Pharmacol 1988;34:311-13
   PubMed Web of Science ®Google Scholar
• Lutz UC, Wiatr G, Gaertner HJ, Bartels M. Oxcarbazepine treatment during breast-feeding: a case report. J Clin Psychopharmacol 2007;27:730-2
   PubMed Web of Science ®Google Scholar
• Lopalco A, Ali H, Denora N, Rytting E. Oxcarbazepine-loaded polymeric nanoparticles: development and permeability studies across in vitro models of the blood–brain barrier and human placental trophoblast. Int J Nanomedicine 2015;10:1985-96
   PubMed Web of Science ®Google Scholar
• Rihtman T, Parush S, Ornoy A. Preliminary findings of the developmental effects of in utero exposure to topiramate. Reproductive Toxicol 2012;34:308-11
   PubMed Web of Science ®Google Scholar
• Kondo T, Kaneko S, Amano Y, Egawa I. Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia 1996;37:1242-4
   PubMed Web of Science ®Google Scholar
• Lawthom C, Smith PE, Wild JM. In utero exposure to vigabatrin: no indication of visual field loss. Epilepsia 2009;50:318-21
   PubMed Web of Science ®Google Scholar
• Tran A, O’Mahoney T, Rey E, et al. Vigabatrin: placental transfer in vivo and excretion into breast milk of the enantiomers. Br J Clin Pharmacol 1998;45:409-11
   PubMed Web of Science ®Google Scholar
• Sharma A, Cavitt J, Privitera M, Moseley BD. Improving the prescription of folate to women receiving antiepileptic drugs. Epilepsy Res 2015;112:27-30
   PubMed Web of Science ®Google Scholar
• Morrow JI, Hunt SJ, Russell AJ, et al. Folic acid use and major congenital malformations in offspring of women with epilepsy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2009;80(5):506-11
   PubMed Web of Science ®Google Scholar
• Koo J, Zavras A. Antiepileptic drugs (AEDs) during pregnancy and risk of congenital jaw and oral malformation. Oral Dis 2013;19:712-20
   PubMed Web of Science ®Google Scholar
• McGrath A, Sharpe L, Lah S, Parratt K. Pregnancy-related knowledge and information needs of women with epilepsy: a systematic review. Epilepsy Behav 2014;31:246-55
   PubMed Web of Science ®Google Scholar
• Tomson T, Marson A, Boon P, et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Veiby G, Engelsen BA, Gilhus NE. Early child development and exposure to antiepileptic drugs prenatally and through breastfeeding: a prospective cohort study on children of women with epilepsy. JAMA Neurology 2013;70:1367-74
   PubMed Web of Science ®Google Scholar
• Vajda FJ, O’Brien TJ, Lander CM, et al. The teratogenicity of the newer antiepileptic drugs - an update. Acta Neurol Scand 2014;130:234-8
   PubMed Web of Science ®Google Scholar
• Meador KJ, Penovich P, Baker GA, et al. Antiepileptic drug use in women of childbearing age. Epilepsy Behav 2009;15:339-43
   PubMedGoogle Scholar
• Fathe K, Palacios A, Finnell RH. Brief report novel mechanism for valproate-induced teratogenicity. Birth Defects Res A Clin Mol Teratol 2014;100:592-7
   PubMed Web of Science ®Google Scholar
• Tomson T, Battino D, Bonizzoni E, et al. EURAP Study Group. Antiepileptic drugs and intrauterine death: A prospective observational study from EURAP. Neurology 2015. [ Epub ahead of print]
   Web of Science ®Google Scholar